BiotechTube

olvimulogene nanivacirepvec + Platinum chemotherapy: carboplatin (preferred) or cisplatin + Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin + Bevacizumab (or biosimilar)

Phase 3Recruiting
0 watching 0 views this week📈 Rising
69
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Platinum-resistant Ovarian Cancer

Conditions

Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, High-grade Serous Ovarian Cancer, Endometrioid Ovarian Cancer, Ovarian Clear Cell Carcinoma

Trial Timeline

Aug 31, 2022 → Oct 1, 2026

NCT ID
NCT05281471

About olvimulogene nanivacirepvec + Platinum chemotherapy: carboplatin (preferred) or cisplatin + Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin + Bevacizumab (or biosimilar)

olvimulogene nanivacirepvec + Platinum chemotherapy: carboplatin (preferred) or cisplatin + Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin + Bevacizumab (or biosimilar) is a phase 3 stage product being developed by Genelux for Platinum-resistant Ovarian Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05281471. Target conditions include Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer, Fallopian Tube Cancer.

Hype Score Breakdown

Clinical
27
Activity
18
Company
2
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT05281471Phase 3Recruiting

Competing Products

16 competing products in Platinum-resistant Ovarian Cancer

See all competitors
ProductCompanyStageHype Score
PRGN-3005 UltraCAR-T cells + PRGN-3005 UltraCAR-T cellsPrecigenPhase 1
28
Niraparib + AnlotinibSun PharmaceuticalPhase 2
52
E7050 + CetuximabEisaiPhase 1/2
41
PLD 40mg/m2 ivgtt q4w +Apatinib 250mg po qd + PLD 40mg/m2 ivgtt q4wJiangsu Hengrui MedicinePhase 2
52
Batiraxcept + DurvalumabAstraZenecaPhase 1/2
41
olaparib+cediranib combination therapy + durvalumab + olaparib combination therapy + durvalumab + chemotherapy treatment + durvalumab + tremelimumab + chemotherapy treatment + durvalumab + tremelimumab + paclitaxel treatment + durvalumab +chemotherapy treatmentAstraZenecaPhase 2
52
Nemvaleukin and Pembrolizumab Combination + Pembrolizumab + Nemvaleukin + Pegylated Liposomal Doxorubicin (PLD) + Paclitaxel + Topotecan + GemcitabineMerckPhase 3
77
CRS-207 + Epacadostat + PembrolizumabIncytePhase 1/2
38
Rina-S + Paclitaxel + Topotecan + Pegylated liposomal doxorubicin (PLD) + GemcitabineGenmabPhase 3
74
Bevacizumab + Irinotecan SucrosofateIpsenPhase 2
49
Gemcitabine + N-803 + M-CENKImmunityBioPhase 2
49
Drug Product De-TIL-0255Nurix TherapeuticsPhase 1
28
Pegylated Liposomal Doxorubicin + SL-172154 + Mirvetuximab + SL-172154Shattuck LabsPhase 1
25
CTIM-76Context TherapeuticsPhase 1
25
LorigerlimabMacroGenicsPhase 2
44
PHI-101 administrationiBioPhase 1
25

Other Products from Genelux

Olvimulogene nanivacirepvec + Platinum chemotherapy: carboplatin or cisplatin + Non-platinum chemotherapy: paclitaxel or nab-paclitaxel for squamous cell NSCLC or pemetrexed for nonsquamous cell NSCLC + Physician's Choice of Immune Checkpoint Inhibitor: pembrolizumab, nivolumab, cemiplimab, atezolizumab, durvalumab + DocetaxelPhase 2
44
GL-ONC1Phase 1/2
33
Olvi-Vec + platinum (cisplatin or carboplatin) + EtoposidePhase 1/2
33
GL-ONC1 alone, or in combination with chemotherapy with or without bevacizumabPhase 1/2
33
GL-ONC1Phase 1
25